Skip to main content

Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception

Author(s): Trussell, James; Hassan, F.; Henry, N.; Pocoski, J.; Law, A.; et al

To refer to this page use:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTrussell, James-
dc.contributor.authorHassan, F.-
dc.contributor.authorHenry, N.-
dc.contributor.authorPocoski, J.-
dc.contributor.authorLaw, A.-
dc.contributor.authorFilonenko, A.-
dc.identifier.citationTrussell, J, Hassan, F, Henry, N, Pocoski, J, Law, A, Filonenko, A. (2014). Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception. Contraception, 89 (451 - 459). doi:10.1016/j.contraception.2013.10.019en_US
dc.description.abstractBackground: Levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg (total content) is a low-dose levonorgestrel intrauterine system for up to 3 years of use. This analysis evaluated the cost-effectiveness of LNG-IUS 13.5 mg in comparison with short-acting reversible contraceptive (SARC) methods in a cohort of young women in the United States from a third-party payer's perspective. Study design: A state transition model consisting of three mutually exclusive health states initial method, unintended pregnancy (UP) and subsequent method was developed. Cost-effectiveness of LNG-IUS 13.5 mg was assessed vs. SARC methods in a cohort of 1000 women aged 20-29 years. SARC methods comprise oral contraceptives (OC), ring, patch and injections, which are the methods commonly used by this cohort. Failure and discontinuation probabilities were based on published literature, contraceptive uptake was determined by the most recent data from the National Survey of Family Growth, and costs were taken from standard US databases. One-way sensitivity analysis was conducted around key inputs, while scenario analysis assessed a comparison between LNG-IUS 13.5 mg and the existing IUS, LNG-IUS 20 mcg/24 h. The key model output was cost per UP avoided. Results: Compared to SARC methods, initiating contraception with LNG-IUS 13.5 mg resulted in fewer UP (64 UP vs. 276 UP) and lower total costs ($1,283,479 USD vs. $1,862,633 USD, a 31% saving) over the 3-year time horizon. Results were most sensitive to the probability of failure on OC, the probability of LNG-IUS 13.5 mg discontinuation and the cost of live births. Scenario analysis suggests that further cost savings may be generated with the initiation of LNG-IUS 20 mcg/24 h in place of SARC methods. Conclusions: From a third-party payer perspective, LNG-IUS 13.5 mg is a more cost-effective contraceptive option than SARC. Therefore, women switching from current SARC use to LNG-IUS 13.5 mg are likely to generate cost savings to third-party health care payers, driven principally by decreased UP-related expenditures and long-term savings in contraceptive costs.en_US
dc.format.extent451 - 459en_US
dc.rightsAuthor's manuscripten_US
dc.titleCost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraceptionen_US
dc.typeJournal Articleen_US

Files in This Item:
File Description SizeFormat 
nihms560733.pdf840.53 kBAdobe PDFView/Download

Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.